Search

Your search keyword '"Nuria González-García"' showing total 2 results
Start Over Author "Nuria González-García" Publisher john wiley and sons inc.
2 results on '"Nuria González-García"'

1. Clinical exacerbation of SARS‐CoV2 infection after fingolimod withdrawal

Author

Paloma Montero-Escribano, Víctor Gómez-Mayordomo, Jorge Matías-Guiu, Nuria González-García, Jordi A. Matías-Guiu, and Jesús Porta-Etessam

Subjects
Drug, Male, Exacerbation, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), media_common.quotation_subject, Short Communication, Short Communications, coronavirus, medicine.disease_cause, multiple sclerosis, SARS‐CoV‐2, 03 medical and health sciences, 0302 clinical medicine, Immune system, exacerbation, Multiple Sclerosis, Relapsing-Remitting, COVID‐19, Virology, medicine, Humans, 030212 general & internal medicine, fingolimod, media_common, Coronavirus, Inflammation, business.industry, Fingolimod Hydrochloride, SARS-CoV-2, Multiple sclerosis, COVID-19, Middle Aged, medicine.disease, Fingolimod, Discontinuation, Infectious Diseases, Immunology, RNA, Viral, 030211 gastroenterology & hepatology, business, Immunosuppressive Agents, medicine.drug
Abstract

The role of disease‐modifying therapies in patients with autoimmune disorders during SARS‐CoV2 infection is controversial. Immunocompromised patients could have a more severe COVID‐19 disease, due to the absence of an adequate immune response against the SARS‐CoV‐2. However, therapies that act on immune response could play a protective role by dampening the cytokine release syndrome. Fingolimod is a drug used for immune therapy in patients with Multiple Sclerosis (MS) through the sequestration of activated lymphocytes in the lymph nodes. We report the case of a 57‐year‐old man with relapsing‐remitting MS treated with fingolimod that showed a reactivation of COVID‐19 with signs of hyperinflammation syndrome after fingolimod withdrawal. Our case suggests that discontinuation of fingolimod during COVID‐19 could imply a worsening of SARS‐CoV2 infection. This article is protected by copyright. All rights reserved.

Published
2020

2. Should We Adapt the Prescription Criteria for Specific Treatments for Migraine Due to the COVID‐19 Pandemic?

Author

Jesús Porta-Etessam, Jordi A. Matías-Guiu, Jorge Matías-Guiu, Paloma Montero-Escribano, and Nuria González-García

Subjects
Adult, medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Migraine Disorders, Pneumonia, Viral, Clinical Neurology, Time-to-Treatment, Betacoronavirus, COVID‐19, Pandemic, medicine, Humans, Medical prescription, Botulinum Toxins, Type A, Pandemics, Botox, business.industry, SARS-CoV-2, COVID-19, Comments, Observations, and Rebuttals, Middle Aged, medicine.disease, onabotulinumtoxinA, Prescriptions, Treatment Outcome, Migraine, Neurology, Views and Perspectives, Emergency medicine, Female, Neurology (clinical), chronic migraine, business, Coronavirus Infections
Abstract

The COVID‐19 pandemic has undoubtedly changed our practice of medicine. With our collective resources and attention focused on caring for those afflicted with the disease, other medical conditions have temporarily but understandably faced constraint. For migraine patients who often require in‐person visits for infusions and procedures, this has become particularly challenging. Here, we share our experience in navigating this exigency amidst a local surge of COVID‐19.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results